Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Clinical Study to Assess the Efficacy and Safety of Dexamethasone Suspension for Cataract Surgery

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03687931
Recruitment Status : Recruiting
First Posted : September 27, 2018
Last Update Posted : September 28, 2018
Sponsor:
Information provided by (Responsible Party):
iDrop, Inc.

Brief Summary:
Patients at least 40 years of age who are undergoing cataract surgery will be randomized to receive treatment with one of two dose levels of dexamethasone ophthalmic suspension eye drops to determine if the drops decrease inflammation inside the eye and are safe after cataract surgery.

Condition or disease Intervention/treatment Phase
Inflammation Eye Drug: Dexamethasone Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1/2 Dose-Ranging, Open-Label, Randomized, Clinical Study to Assess the Efficacy and Safety of Dexamethasone Ophthalmic Suspension Eye Drops for the Treatment of Inflammation Associated With Cataract Surgery
Actual Study Start Date : August 26, 2018
Estimated Primary Completion Date : February 2019
Estimated Study Completion Date : February 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Cataract

Arm Intervention/treatment
Experimental: Arm 1
Dexamethasone suspension dose level 1
Drug: Dexamethasone
Drop

Experimental: Arm 2
Dexamethasone suspension dose level 2
Drug: Dexamethasone
Drop




Primary Outcome Measures :
  1. Anterior Chamber Cell [ Time Frame: 30 days ]
    Number of cells in the anterior chamber



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   40 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male or female patients at least 40 years of age scheduled for unilateral cataract surgery by phacoemulsification with posterior chamber intraocular lens implantation.

Exclusion Criteria:

  • Patients who have received a periocular corticosteroid injection in the study eye in the 3 months prior to screening.
  • Patients who anticipate requiring treatment with any corticosteroids by any route, except inhalation, during the study.
  • Patients who are known steroid responders

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03687931


Contacts
Layout table for location contacts
Contact: William White 205-306-8834 wsandywhite@gmail.com

Locations
Layout table for location information
United States, Arizona
Arizona Eye Center Recruiting
Chandler, Arizona, United States, 85224
Contact: Michael Depenbusch, MD         
Sponsors and Collaborators
iDrop, Inc.
Investigators
Layout table for investigator information
Study Chair: William White iDrop, Inc.

Layout table for additonal information
Responsible Party: iDrop, Inc.
ClinicalTrials.gov Identifier: NCT03687931     History of Changes
Other Study ID Numbers: C-01
First Posted: September 27, 2018    Key Record Dates
Last Update Posted: September 28, 2018
Last Verified: September 2018

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Cataract
Eye Diseases
Inflammation
Pathologic Processes
Lens Diseases
Dexamethasone
Dexamethasone acetate
BB 1101
Anti-Inflammatory Agents
Antiemetics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action